Výsledky vyhledávání - "Hans Benno Leicht"

Akademický článek

Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events

Publikováno v: JHEP Reports, Vol 6, Iss 6, Pp 101065- (2024)

Background & Aims: Atezolizumab/bevacizumab (atezo/bev) and lenvatinib have demonstrated efficacy as first-line therapies for hepatocellular carcinoma (HCC). However, vascular endothelial growth factor (VEGF) inhibition with these therapies may be as

Externí odkaz: https://doaj.org/article/8bfa5b4342fd47ce9b2a38f731714629

Zobrazit plný text záznamu

Akademický článek

Autor: Bianca Heller, Florian P. Reiter, Hans Benno Leicht, Cornelia Fiessler, Ina Bergheim, Peter U. Heuschmann, Andreas Geier, Monika Rau

Publikováno v: Nutrients, Vol 15, Iss 18, p 3942 (2023)

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) imposes a significant burden on Westernized regions. The Western diet, high in salt intake, significantly contributes to disease development. However, there are a lack of da

Externí odkaz: https://doaj.org/article/195831fe710c4cc8961dd862c7ed05c9

Zobrazit plný text záznamu

Akademický článek

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ('Pom‐PAD‐Dara') in relapsed/refractory multiple myeloma

Autor: Xiang Zhou, Maximilian J. Steinhardt, Denise Grathwohl, Katharina Meckel, Katharina Nickel, Hans‐Benno Leicht, Franziska Krummenast, Hermann Einsele, Leo Rasche, Klaus M. Kortüm

Publikováno v: Cancer Medicine, Vol 9, Iss 16, Pp 5819-5826 (2020)

Abstract Background Even in the era of novel immunotherapies for multiple myeloma (MM), treatment of late‐stage relapsed/refractory (RR) patients remains challenging. The aim of our study was to analyze the efficacy and safety of the five‐drug co

Externí odkaz: https://doaj.org/article/de8c2d8802274012a1aac441c04130c1

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature

Autor: Hans Benno Leicht, Elke Weinig, Beate Mayer, Johannes Viebahn, Andreas Geier, Monika Rau

Publikováno v: BMC Pharmacology and Toxicology, Vol 19, Iss 1, Pp 1-7 (2018)

Abstract Background Drug induced immune hemolytic anemia (DIIHA) is a rare complication and often underdiagnosed. DIIHA is frequently associated with a bad outcome, including organ failure and even death. For the last decades, ceftriaxone has been on

Externí odkaz: https://doaj.org/article/eb7da9840a4242aabdfba2e8b648ed2f

Zobrazit plný text záznamu